Skip to content

Stool therapy for improvement in liver disease

Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy: A Randomized Controlled Trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039314
Enrollment
66
Registered
2022-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Fecal Microbiota transplant and Standard Medical Treatment: FMT: Three doses (30ml one dose) of FMT will be given via jejunal port of NJ/NG tube once daily for 3 days. SMT: Lactulose

Sponsors

Institute of Liver and Biliary Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cirrhotic patients between 18 years to 70 years, who have recovered within 7 days from hepatic encephalopathy after hospitalization

Exclusion criteria

Exclusion criteria: 1.Patient having hepatic encephalopathy after obvious precipitants 2.Patients on immunosuppressive medications 3.Active Infection (documented blood culture positive, Imaging diagnosis or SIRS more than equals to 1) 4.AKI (Defined as per KIDGO guidelines) 5.GI Bleed (In past 14 days) 6.Hepatocellular carcinoma 7.Patient with portosystemic shunt with size more than 10mm 8.Patients with previous TIPS or shunt surgery 9.Patients with significant comorbid illness such as heart, respiratory, or renal failure 10.Any neurologic diseases such as Alzheimer disease, Parkinson disease 11.Non hepatic metabolic encephalopathies 12.Not willing for the study

Design outcomes

Primary

MeasureTime frame
Proportion of patients developing an episode of hepatic encephalopathy within 6 monthsTimepoint: 6 months

Secondary

MeasureTime frame
Change in Ammonia level and Psychometric test/CFF pre and post FMTTimepoint: Day 28,90,180;Change in CTP and MELD scoreTimepoint: Day 28,90,180;Change in inflammatory markers pre and post FMTTimepoint: Day 28,90,180;Change in Stool microbiome and metabolomics and urinary metabolomics pre and post FMTTimepoint: Day 28,90,180;Proportion of patients developing adverse event related to FMT within 6 monthsTimepoint: 6 months;Transplant free survivalTimepoint: Day 28,90 and 180 days

Countries

India

Contacts

Public ContactDr Shiv Kumar Sarin

Institute of Liver and Biliary Sciences

shivsarin@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026